| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 建材业务分部(元) | 224,150,328.17 | 544,882,622.11 | 274,074,111.11 | 593,978,109.55 | 261,309,174.95 |
| 私募股权投资基金管理业务分部(元) | 142,371,767.83 | 380,489,450.11 | 209,899,031.60 | 452,061,884.49 | 221,116,249.76 |
| 生物医药业务分部(元) | 166,006,025.01 | 280,138,043.79 | 145,224,647.37 | 28,517,684.77 | - |
| 营业成本(元) | |||||
| 建材业务分部(元) | 208,109,122.69 | 543,063,312.30 | 296,386,644.96 | 555,667,081.65 | 248,559,091.95 |
| 私募股权投资基金管理业务分部(元) | 2,740,682.61 | 1,582,973.62 | - | - | - |
| 生物医药业务分部(元) | 90,084,704.63 | 200,089,968.34 | 110,975,687.66 | 25,889,297.25 | - |
| 毛利(元) | |||||
| 建材业务分部(元) | 16,041,205.48 | 1,819,309.81 | -22,312,533.85 | 38,311,027.90 | 12,750,083.00 |
| 私募股权投资基金管理业务分部(元) | 139,631,085.22 | 378,906,476.49 | 209,899,031.60 | 452,061,884.49 | 221,116,249.76 |
| 生物医药业务分部(元) | 75,921,320.38 | 80,048,075.45 | 34,248,959.71 | 2,628,387.52 | - |
| 毛利率(%) | |||||
| 建材业务分部(%) | 7.16 | 0.33 | -8.14 | 6.45 | 4.88 |
| 私募股权投资基金管理业务分部(%) | 98.07 | 99.58 | - | - | - |
| 生物医药业务分部(%) | 45.73 | 28.57 | 23.58 | 9.22 | - |
| 收入构成(%) | |||||
| 建材业务分部(%) | 42.09 | 45.20 | 43.56 | 55.28 | 54.17 |
| 私募股权投资基金管理业务分部(%) | 26.74 | 31.56 | 33.36 | 42.07 | 45.83 |
| 生物医药业务分部(%) | 31.17 | 23.24 | 23.08 | 2.65 | - |
| 毛利构成(%) | |||||
| 建材业务分部(%) | 6.93 | 0.39 | -10.06 | 7.77 | 5.45 |
| 私募股权投资基金管理业务分部(%) | 60.29 | 82.23 | 94.62 | 91.70 | 94.55 |
| 生物医药业务分部(%) | 32.78 | 17.37 | 15.44 | 0.53 | - |